Mechanisms of drug resistance in Mycobacterium tuberculosis and current status of rapid molecular diagnostic testing

Acta Tropica

Volumn 119, Issue 1, 2011, Pages 5-10

  Laurenzo, David ^a   Mousa, Shaker A ^a,b  

^a Pharmaceutical Research Institute at Albany   (United States)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Drug resistant; Ethionamide; Isoniazid; Rapid detection; Rifampin; Tuberculosis

Indexed keywords

AMIKACIN; ARABINOSYLTRANSFERASE; BACTERIAL ENZYME; CAPREOMYCIN; DNA DIRECTED RNA POLYMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; KATG PROTEIN; MYCOLIC ACID; PROTEIN EMB; PROTEIN ETAA; PROTEIN ETAR; PYRAZINAMIDASE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; REGULATOR PROTEIN; RIBOSOME PROTEIN; RIBOSOME PROTEIN S12; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG;

BACTERIUM; DRUG RESISTANCE; PUBLIC HEALTH; TUBERCULOSIS;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; BACTERIAL CELL WALL; BACTERIAL GENE; BASE PAIRING; CODON; CROSS RESISTANCE; DNA SEQUENCE; DRUG MECHANISM; DRUG RESISTANT TUBERCULOSIS; DRUG TARGETING; GENE MUTATION; HUMAN; INHA GENE; LOOP MEDIATED ISOTHERMAL AMPLIFICATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PNCA GENE; PROTEIN SYNTHESIS INHIBITION; RPSL GENE; RRS GENE; SENSITIVITY AND SPECIFICITY; STRUCTURAL GENE; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 79957595650     PISSN: 0001706X     EISSN: 0001706X     Source Type: Journal    
DOI: 10.1016/j.actatropica.2011.04.008     Document Type: Review

References (56)

1. Ahmad S., Al-Mutairi N.M., Mokaddas E. Comparison of performance of two DNA line probe assays for rapid detection of multidrug-resistant isolates of Mycobacterium tuberculosis. Indian J. Exp. Biol. 2009, 47:454-462.
2. Alangaden G.J., Kreiswirth B.N., Aouad A., Khetarpal M., Igno F.R., Moghazeh S.L., Manavathu E.K., Lerner S.A. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1998, 42:1295-1297.
3. Ando H., Mitarai S., Kondo Y., Suetake T., Kato S., Mori T., Kirikae T. Evaluation of a line probe assay for the rapid detection of gyrA mutations associated with fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis. J. Med. Microbiol. 2011, 60(Part 2):184-188.
4. Ando H., Mitarai S., Kondo Y., Suetake T., Sekiguchi J.I., Kato S., Mori T., Kirikae T. Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Japan. Clin. Microbiol. Infect. 2010, 16(8):1164-1168.
5. Barnard M., Albert H., Coetzee G., O'Brien R., Bosman M.E. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am. J. Respir. Crit. Care Med. 2008, 177:787-792.
6. Basso L.A., Zheng R., Musser J.M., Jacobs W.R., Blanchard J.S. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J. Infect. Dis. 1998, 178:769-775.
7. Bwanga F., Hoffner S., Haile M., Joloba M.L. Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. BMC Infect. Dis. 2009, 9:67.
8. Cheng S.J., Thibert L., Sanchez T., Heifets L., Zhang Y. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob. Agents Chemother. 2000, 44:528-532.
9. Cooksey R.C., Morlock G.P., McQueen A., Glickman S.E., Crawford J.T. Characterization of streptomycin resistance mechanisms among Mycobacterium tuberculosis isolates from patients in New York City. Antimicrob. Agents Chemother. 1996, 40:1186-1188.
10. Dalla Costa E.R., Ribeiro M.O., Silva M.S., Arnold L.S., Rostirolla D.C., Cafrune P.I., Espinoza R.C., Palaci M., Telles M.A., Ritacco V., Suffys P.N., Lopes M.L., Campelo C.L., Miranda S.S., Kremer K., da Silva P.E., Fonseca Lde S., Ho J.L., Kritski A.L., Rossetti M.L. Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America. BMC Microbiol. 2009, 9:39.
11. DeBarber A.E., Mdluli K., Bosman M., Bekker L.G., Barry C.E. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:9677-9682.
12. Doctorswithoutborders.org Tuberculosis Diagnosis and Drug Sensitivity Testing. An Overview of the Current Diagnostic Pipiline 2006, Campaign for Access to Essential Medicines, New York.
13. Gillespie S.H. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob. Agents Chemother. 2002, 46:267-274.
14. Ginsburg A.S., Grosset J.H., Bishai W.R. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. 2003, 3:432-442.
15. Guo H., Seet Q., Denkin S., Parsons L., Zhang Y. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J. Med. Microbiol. 2006, 55:1527-1531.
16. Hazbon M.H., Brimacombe M., Bobadilla del Valle M., Cavatore M., Guerrero M.I., Varma-Basil M., Billman-Jacobe H., Lavender C., Fyfe J., Garcia-Garcia L., Leon C.I., Bose M., Chaves F., Murray M., Eisenach K.D., Sifuentes-Osornio J., Cave M.D., Ponce de Leon A., Alland D. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2006, 50:2640-2649.
17. Heep M., Rieger U., Beck D., Lehn N. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2000, 44:1075-1077.
18. Hillemann D., Rusch-Gerdes S., Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 2009, 47:1767-1772.
19. Isturiz R. Global resistance trends and the potential impact on empirical therapy. Int. J. Antimicrob. Agents 2008, 32(Suppl. 4):S201-206.
20. Jureen P., Werngren J., Toro J.C., Hoffner S. Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2008, 52:1852-1854.
21. Kiepiela P., Bishop K.S., Smith A.N., Roux L., York D.F. Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa. Tuber. Lung Dis. 2000, 80:47-56.
22. Kim S.J. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur. Respir. J. 2005, 25:564-569.
23. Lange C., Mori T. Advances in the diagnosis of tuberculosis. Respirology 2010, 15:220-240.
24. Lee A.S., Lim I.H., Tang L.L., Telenti A., Wong S.Y. Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore. Antimicrob. Agents Chemother. 1999, 43:2087-2089.
25. Lee A.S., Teo A.S., Wong S.Y. Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 2001, 45:2157-2159.
26. Ling D.I., Zwerling A.A., Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur. Respir. J. 2008, 32:1165-1174.
27. Long R. Drug-resistant tuberculosis. CMAJ 2000, 163:425-428.
28. Maus C.E., Plikaytis B.B., Shinnick T.M. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2005, 49:3192-3197.
29. Mdluli K., Slayden R.A., Zhu Y., Ramaswamy S., Pan X., Mead D., Crane D.D., Musser J.M., Barry C.E. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science 1998, 280:1607-1610.
30. Mitchison D.A., Nunn A.J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am. Rev. Respir. Dis. 1986, 133:423-430.
31. Moghazeh S.L., Pan X., Arain T., Stover C.K., Musser J.M., Kreiswirth B.N. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob. Agents Chemother. 1996, 40:2655-2657.
32. Mori Y., Hirano T., Notomi T. Sequence specific visual detection of LAMP reactions by addition of cationic polymers. BMC Biotechnol. 2006, 6:3.
33. Musser J.M., Kapur V., Williams D.L., Kreiswirth B.N., van Soolingen D., van Embden J.D. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J. Infect. Dis. 1996, 173:196-202.
34. Pai, M., 2009. Evidence-based Tuberculosis Diagnosis, Montreal.
35. Ramaswamy S., Musser J.M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis. 1998, 79:3-29.
36. Rouse D.A., Li Z., Bai G.H., Morris S.L. Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1995, 39:2472-2477.
37. Scorpio A., Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 1996, 2:662-667.
38. Sekiguchi J., Nakamura T., Miyoshi-Akiyama T., Kirikae F., Kobayashi I., Augustynowicz-Kopec E., Zwolska Z., Morita K., Suetake T., Yoshida H., Kato S., Mori T., Kirikae T. Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains. J. Clin. Microbiol. 2007, 45(9):2802-2807.
39. Somoskovi A., Parsons L.M., Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir. Res. 2001, 2:164-168.
40. Sreevatsan S., Pan X., Stockbauer K.E., Williams D.L., Kreiswirth B.N., Musser J.M. Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities. Antimicrob. Agents Chemother. 1996, 40:1024-1026.
41. Sreevatsan S., Stockbauer K.E., Pan X., Kreiswirth B.N., Moghazeh S.L., Jacobs W.R., Telenti A., Musser J.M. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob. Agents Chemother. 1997, 41:1677-1681.
42. Takiff H.E., Salazar L., Guerrero C., Philipp W., Huang W.M., Kreiswirth B., Cole S.T., Jacobs W.R., Telenti A. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother. 1994, 38:773-780.
43. Tbevidence.org Evidence-based Tuberculosis Diagnosis 2009, Stop TB Partnership's New Diagnostics Working Group, Montreal. M. Pai (Ed.).
44. Telenti A., Imboden P., Marchesi F., Lowrie D., Cole S., Colston M.J., Matter L., Schopfer K., Bodmer T. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993, 341:647-650.
45. Telenti A., Philipp W.J., Sreevatsan S., Bernasconi C., Stockbauer K.E., Wieles B., Musser J.M., Jacobs W.R. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat. Med. 1997, 3:567-570.
46. US Centers for Disease Control, 2007. United States Centers for Disease Control, Atlanta.
47. US Centers for Disease Control Multidrug-Resistant Tuberculosis (MDR TB) Fact Sheet 2010, United States Centers for Disease Control, Atlanta.
48. US Department of Health and Human Services, F.a.D.A., 2010. The Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals, Draft Guidance.
49. US Food and Drug Administration, 2008. FDA's Role in Antimicrobial Resistance.
50. van Doorn H.R., An D.D., de Jong M.D., Lan N.T., Hoa D.V., Quy H.T., Chau N.V., Duy P.M., Tho D.Q., Chinh N.T., Farrar J.J., Caws M. Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-time PCR. Int. J. Tuberc. Lung Dis. 2008, 12:736-742.
51. Wade M.M., Zhang Y. Mechanisms of drug resistance in Mycobacterium tuberculosis. Front. Biosci. 2004, 9:975-994.
52. Williams D.L., Spring L., Collins L., Miller L.P., Heifets L.B., Gangadharam P.R., Gillis T.P. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1998, 42:1853-1857.
53. Zell B.L., Goldmann D.A. Healthcare-associated infection and antimicrobial resistance: moving beyond description to prevention. Infect. Control Hosp. Epidemiol. 2007, 28:261-264.
54. Zhang Y., Heym B., Allen B., Young D., Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992, 358:591-593.
55. Zhang Y., Wade M.M., Scorpio A., Zhang H., Sun Z. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother. 2003, 52(5):790-795.
56. Zhang Y., Yew W.W. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2009, 13:1320-1330.